Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03325127
Title Outcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review Study
Recruitment Withdrawn
Gender male
Phase Phase I
Variant Requirements No
Sponsors Bayer

prostate cancer


Abiraterone + Enzalutamide + Radium Ra 223 dichloride

Age Groups: adult | senior
Covered Countries

No variant requirements are available.